SPA
ABEO icon

Sherbrooke Park Advisers’s Abeona Therapeutics ABEO Stock Holding History

Sherbrooke Park Advisers’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$82K Buy
15,556
+3,377
+28% +$17K 0.21% 140
2025
Q3 		$64.3K Buy
+12,179
New +$77.2K 0.03% 482

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Sherbrooke Park Advisers's ABEO Position: Q4 2025 in Review

Sherbrooke Park Advisers increased its Abeona Therapeutics (ABEO) stake by 28% in Q4 2025, buying an estimated $17K and bringing the position to 15,556 shares worth $82K. The position accounts for 0.21% of the portfolio, ranked #140.

Sherbrooke Park Advisers first reported a position in ABEO in Q3 2025 and has held it in 2 quarters since. 104 funds tracked by Wall St. Rank hold ABEO as of Q4 2025.

  • Sherbrooke Park Advisers held 15,556 shares of Abeona Therapeutics worth $82K as of Q4 2025.
  • Sherbrooke Park Advisers bought 3,377 Abeona Therapeutics shares in Q4 2025, an estimated $17K.
  • Abeona Therapeutics made up 0.21% of Sherbrooke Park Advisers's portfolio in Q4 2025, its #140 holding.
  • Sherbrooke Park Advisers first reported a position in Abeona Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 104 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q4 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.